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Community-Acquired Pneumonia (CAP) is a major public health problem. In Brazil it has been estimated that
2,000,000 people are affected by CAP every year. Of those, 780,000 are admitted to hospital, and 30,000 have death as
the outcome. This is an open-label, non-comparative study with the purpose of evaluating efficacy, safety, and
tolerability levels of IV azithromycin (IVA) and IV ceftriaxone (IVC), followed by oral azithromycin (OA) for the
treatment of inpatients with mild to severe CAP. Eighty-six patients (mean age 56.6 ± 19.8) were administered IVA
(500mg/day) and IVC (1g/day) for 2 to 5 days, followed by AO (500mg/day) to complete a total of 10 days. At the end
of treatment (EOT) and after 30 days (End of Study - EOS) the medication was evaluated clinically, microbiologically
and for tolerability levels. Out of the total 86-patient population, 62 (72.1%) completed the study. At the end of
treatment, 95.2% (CI95: 88.9% – 100%) reported cure or clinical improvement; at the end of the study, that figure
was 88.9% (CI95: 74.1% – 91.7%). Out of the 86 patients enrolled in the study, 15 were microbiologically evaluable
for bacteriological response. Of those, 6 reported pathogen eradication at the end of therapy (40%), and 8 reported
presumed eradication (53.3%). At end of study evaluation, 9 patients showed pathogen eradication (50%), and 7
showed presumed eradication (38.89%). Therefore, negative cultures were obtained from 93.3% of the patients at
EOT, and from 88.9% at the end of the study. One patient (6.67% of patient population) reported presumed
microbiological resistance. At study end, 2 patients (11.11%) still reported undetermined culture. Uncontrollable
vomiting and worsening pneumonia condition were reported by 2.3% of patients.
Discussion and Conclusion Treatment based on the administration of IV azithromycin associated to ceftriaxone and
followed by oral azithromycin proved to be efficacious and well-tolerated in the treatment of Brazilian inpatients
with CAP.
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Community-Acquired Pneumonia (CAP) is a major public
health problem. The estimated yearly incidence in the United
States is 4 million cases [1]. Of those, 600,000 are admitted to
hospital, with death being the outcome for up to 40% [2] and
with costs reaching 23 billion dollars [3,4]. In Brazil, CAP affects
2 million people annually, being the second most common
cause of hospital admittance: 780,000, with 30,000 having death
as the outcome. Appropriate microbiological exams identify
infection-causing microorganisms in less than 50% of cases
[5,6]. Therefore, the administration of antibiotics is based on
results from clinical and epidemiological studies, being
eminently empirical and usually administered to fight
Streptococcus pneumoniae and Haemophilus influenzae:
typically, the most frequently isolated microorganisms in adult
patients admitted due to CAP. Pneumococcus is still the
“number 1” pathogen in all age ranges, with penicillin
resistance variable at different geographical locations
worldwide: in Brazil, it is approximately 2%-5%, being typically
presented as an invasive pneumococcic condition, which
means that it is with bacteremia, empyema or concurrent
meningitis.
Brandileone et al. carried out an evaluation through CLSI/
NCCLS clinical and laboratory interpretation endpoints for
disc diffusion susceptibility and MIC results. Approximately
5.9% of pneumococci presented “high-level resistance”,
and approximately 22% presented “intermediate level
resistance” [7].
CAP treatment is changeable, and tries to track down
microorganisms. In 1993, the American Thoracic Society (ATS)
published guidelines for the treatment of CAP. Those
guidelines recommended that inpatients should receive
empirical therapy based on the association of a beta-lactam
and a macrolide [7], so that atypical agents (Mycoplasma,
Chlamydophila pneumoniae (Chlamydia) and Legionella)
could be covered. Atypical bacteria account for 15%-20% of
hospital admittances due to CAP; therefore, in many cases,
diagnosis is not predictable based on clinical and/or
radiological conditions.
Studies have demonstrated that if that association is
administered within 24 hours of admission, hospitalization
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time will be reduced by 50% [8,9]. Those recommendations
were slightly changed in 2000, and confirmed in 2007, with the
possibility of administering fluoroquinolones to inpatients
with CAP as well as antibiotic therapy starting within 4 hours
of admission at the latest [10].
In Brazil, the Brazilian Society of Pneumology and Tisiology
published guidelines for the treatment of CAP in 2004. The
guidelines recommend a systematic approach after the decision
had been made as to whether treatment will be in hospital or
through the outpatient unit. The guidelines set out that,
inpatients on the ward must receive the association of a
macrolide and a third generation cephalosporin or a macrolide
associated to a betalactamic and to a beta-lactamase inhibitor
(IV) or a fluoroquinolone [11-15]. However, the use of
fluoroquinolones has been at the core of debates for the last
10 years due to its potential ability to induce resistance, as
well as tolerability problems, especially among patients with
comorbidities. That led the CDC to recommend use restriction
for conditions requiring an empirical approach [16]. Although
Brazil has never reported resistance of S. pneumoniae invasive
strains to fluoroquinolones, fast-pace emergence of Gram-
negative bacteria that were resistant to a number of antibiotic
classes was observed at hospitals where fluoroquinolone
administration was under no restriction in treating respiratory
infections, which makes therapy management of infections
acquired in that setting more difficult [17]. In February, 2007
Metersky et al. conducted a multivariate analysis of CAP
treatment. They observed that the empirical use of
fluoroquinolone may be harmful and does not impact on the
mortality rate [18], as opposed to the association of a macrolide
and a third generation cephalosporin, which impacts positively
[19]. In Canada, S. pneumoniae resistant to quinolones was
detected concurrent to increased use of fluoroquinolone to
treat CAP [20]. The work mentioned earlier, by Brandileone
and cols., showed that 6.2% of the 3,817 S. pneumoniae strains
tested were erythromycin resistant. S. pneumoniae resistance
to macrolides differs in the United States and in Europe. Major
approaches to CAP treatment also differ. In North America
macrolides are more widely used, especially due to the fact
that pathogen resistance to macrolides is mediated through
efflux pumps (low level), whereas in Europe the resistance
process takes place through ribosomic site change (high level).
The understanding of the macrolide efficacy and tolerability
profile in different ethnic groups was turned into a key aspect
in such complex scenarios.
A number of factors were taken into account for macrolide
choice making. Azithromycin belongs to the azalide subclass
in the macrolide antibiotic class, with a proven in vitro and in
vivo action spectrum against major pneumonia-causing agents:
S. pneumoniae, H. influenzae, C. pneumoniae, L.
pneumophila, M. catarrhalis, M. pneumoniae and S. aureus
(oxacillin sensitive). Since approval in the United States in
1997, azithromycin IV formulation has been widely used for
inpatients with CAP. In addition to action spectrum,
azithromycin pharmacokinetics and high tissue levels allow a
single daily dose regimen. When CAP patients are treated in
the outpatient unit, those pharmacological properties allow
the use of azithromycin as monotherapy [21]. The purpose of
the present study was to evaluate the efficacy, safety and
tolerability of a combined regimen – azithromycin and
ceftriaxone – both IV, followed by oral azithromycin when
treating inpatients with moderate to severe CAP.
This is the first scientific paper in Brazil to show the efficacy
of ceftriaxone + azithromycin to treat CAP in the Brazilian
population scenario.
Materials and Methods
Eligibility Criteria
Both male and female patients over 18 years old, with
history, clinical and radiological findings consistent with CPA
diagnosis and whose severity required hospitalization and
initial therapy with IV antibiotics were eligible to enroll in the
study. The following criteria had to be met: (1) presence of
alveolar infiltrate at thoracic X-ray, and at least two of the
following findings within 48 hours prior to first visit (Visit I):
onset of cough or worsening of chronic cough; change in
sputum characteristics; axillary temperature > 38oC (fever) or
< 36.1oC (hypothermia) in the previous 24 hours; pulmonary
auscultation compatible with consolidation (fine bubbling
rale); and leukocytosis (leukocytes > 10,000/mm3 or > 15%
young leukocytes); (2) presence of any score in severity
criteria for coexistent diseases in the Pneumonia Severity
Index (PSI) or any PSI score that would classify a patient as
≥II [22]. Pregnant or lactating women patients were excluded,
as well as women of childbearing age not using effective
contraceptives. Also excluded were patients presenting the
following conditions/treatment: allergies or known or
suspected intolerance to penicillin, cephalosporin, or
macrolides; systemic treatment with any antibiotic for any
period longer than 24 hours prior to first visit, or longer than
seven days in the previous month; AIDS patients,
neutropenics, (leukocytes < 2,500/mm3 or neutrophils <1,000/
mm3) or undergoing chronic immunosuppressant therapy;
clinical or radiological signs of pulmonary cavitation; cystic
fibrosis, primary or metastatic pulmonary neoplasia, aspiration
pneumonia, pleural empyema, tuberculosis or bronchiecstasis;
gastrointestinal disorders or any other condition affecting
the drug under investigation; epilepsy or seizures; clinically
significant renal failure - creatinine > 2.0 mg/dL, or estimated
creatinine clearance < 20 mL/min/1.73 m2 of body surface area;
evidence of clinically significant hepatic failure with
transaminase levels three times above the normal upper limit,
or total bilirubin levels twice the upper normal limit; clinically
significant cardiovascular condition. Patients participating in
any other study involving investigational or commercial drugs
concurrently or having participated within a month before the
start of the present study were also excluded, as were those
who had previously participated in the present study, those
with evidence of recent alcohol or illegal drug abuse; and
those who presented any condition which, following
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investigators’ discretion, could interfere in their safety, their
treatment response assessment, or that could in any way
preclude treatment completion or follow-up; and those who
had donated blood less than four weeks before study starting
date or who planned to donate blood within a time period of
four weeks after study completion. Childbearing age women
who had not been surgically sterilized had to undergo a
pregnancy test immediately before the study started.
Additionally, effective contraceptive methods were expected
to be in use during treatment period and for 10 days after
study close. All patients included in the study signed the
informed consent form. Study protocol was pre-approved by
the Research Ethics Committee at each of the 13 institutions
participating in the study. The study was conducted in
compliance with Good Clinical Research Practices, the ethic
principles of the Declaration of Helsinki, and the Brazilian
legislation with regard to clinical research.
Study Design
This was a 30-day open-label, multicenter, non-comparative
study. The study drug was administered for a period of 10
days. The average number of patients per center was 7. The
center with the highest number of patients had a total of 30
enrollments. CAP patients who fulfilled the eligibility criteria
were enrolled in the study. All patients received a single daily
dose of 500 mg of azithromycin associated to 1g of ceftriaxone
(IV) for a period of between 2 and 5 days. Treatment proceeded
with a single daily dose of 500 mg of oral azithromycin to
complete 10 treatment days. For cases where S. pneumoniae
resistant to a macrolide was isolated in culture, the association
of cefuroxime axetil and oral azithromycin was allowed. Patients
were evaluated at enrollment (Visit I), on Visit II (day 3), at the
end of treatment (Visit III – day 10-12), and by study
completion (Visit IV – day 28 to 35), as well as daily during
hospitalization. Clinical and bacteriological safety assessment
was carried out at Visits I, III, and IV. Patients who finished
treatment were still evaluated for safety for a period of 30
days. On Visit I the following data were collected:
demographics, comorbidity history, information on the use of
antibiotics in the previous month, medications currently being
used, and information from an objective physical exam, which
included measures of vital signs (heart and respiratory rate,
blood pressure and temperature). Clinical evaluation of
pneumonia signs and symptoms involved sputum
characteristics, cough, dyspnea, pleuritic pain, rigors and
adventitious sounds at pulmonary auscultation. Two chest
X-Rays were taken: frontal and lateral view. PSI determination
criteria were also evaluated, which resulted in a PSI score [22].
Blood and urine samples were collected for safety laboratory
analysis. Childbearing age female patients were submitted to
pregnancy test (urine or blood). Whenever possible, proper
sputum samples – defined as a sample with > 25
polymorphonuclear leukocytes and < than 10 epithelial cells
per 100 x field after Gram’s stain test - and blood samples were
obtained for culture. The sputum samples were submitted to
microbiological qualitative evaluation only. Those showing
bacterial growth were submitted to an antibiogram and tested
locally at the center’s laboratory with regard to antibiotic
susceptibility following the National Committee for Clinical
Laboratory Standards criteria. All patients enrolled in the
study had blood samples taken for hemoculture locally at the
center’s laboratory. During the same visit urine samples were
collected to detect Streptococcus pneumoniae and Legionella.
Ideally, three sputum samples and hemoculture should have
been collected for evaluation.
On Visit II (day3) the need for IV antibiotic therapy was
assessed. The change to oral therapy was seen as appropriate
whenever all of the criteria below were present: (1) body
temperature < 37.8oC for a minimum of 8 hours; (2) cough and
dyspnea condition improvement; (3) proper oral intake and
absorption; (4) leukocytosis reduction as compared to
baseline. All signs and symptoms identified in Visit I were
reevaluated. New ones were reported. Hematological and
biochemical laboratory exams were repeated. Whenever
possible, a second proper sample was obtained for sputum
culture. If no expectoration was present even after nebulization
and physiotherapy, culture was considered negative.
Hemoculture collection was repeated if Visit I collection was
positive, or if the patient had been discontinued from the
study due to therapeutic failure.
At the end of treatment (Visit III, day 10 to 12), global
clinical response to treatment was evaluated and classified as
cure, improvement or therapeutic failure. Each of them were
defined as follows: (1) cure: the resolution of signs and
symptoms, with clinical recovery to before the occurrence of
pneumonia condition, which included leukocytosis reduction,
with improvement or non-progression of infiltrates at thoracic
X-Ray; (2) improvement, as resolution of fever, but incomplete
resolution of other signs and symptoms, with no need for
additional antibiotic therapy; (3) therapeutic failure, such as
no resolution or worsening of any of pneumonia signs or
symptoms, with the need for additional antibiotic therapy.
Therapeutic failure might be associated to the antibiotic – in
the case that the patient had been administered the study
drug for at least 48 hours – or non-related to the antibiotic – in
the case that the patient had been administered the drug for
less than 48 hours; (4) undetermined – when patient response
to treatment could not be evaluated (lost due to follow-up or
study withdrawal, except when due to therapeutic failure,
among other reasons). At study close (Visit IV, days 28 to 35)
or at early discontinuation, the investigator conducted a final
evaluation of the global clinical response to treatment.
Classification was: cure, improvement, or therapeutic failure.
Both, signs and symptoms that were identified at earlier visits,
and new ones that might have emerged, were compared. Those
signs and symptoms were all compared to Visit I. Vital signs
were also evaluated, as well as concurrent use of other
medications and the occurrence of adverse events.
Hematological and biochemical exams were repeated only if a
clinically significant adverse event occurred, or if any relevant
Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of CAP
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laboratory change was detected at Visit III. A final thoracic X-
ray was taken, and whenever possible, a proper sample was
obtained for sputum culture. If no sample could be obtained,
it was considered equivalent to a negative culture. If initial
hemoculture was positive, or if the patient was discontinued
due to clinical failure, a new sample was collected for blood
culture.
Efficacy and Safety Evaluation
The sample from intention to treat (ITT) patients included
those who received at least one dose of IV azithromycin, and
who provided sufficient data for at least one efficacy parameter
analysis, conducted separately from clinical and bacteriological
response. Primary efficacy parameter was clinical response,
defined as the percentage of cure or improvement at the end
of the study. Secondary efficacy parameters were clinical
response at the end of the study and bacteriological response
rate at the end of treatment (Visit III) and at end of the study
(Visit IV). Clinical response was determined by comparing
clinical presentation global evaluation at study end and Visit
I. Bacteriological response was evaluated at the end of
treatment (Visit III) and at the end of study (Visit IV), having
been defined as follows: (1) eradication, when the isolated
pathogen was eliminated early, in same site sample (sputum
or blood); (2) presumed eradication, in the absence of a proper
sputum sample, associated to clinical improvement; (3)
persistence, when the eradication of the infection causing
agent was not achieved; (4) relapse, when the pathogen
isolated at Visit I was again present within 5 days of treatment
discontinuation, or during treatment, after a second negative
culture; (5) super infection, a new infection in the lower
respiratory tract – documented by thoracic X-Ray or pulmonary
auscultation, during treatment or up to three days after close
of treatment – caused by a new pathogen or by a resistant
pathogen; (6) colonization, when sputum culture was positive
for a bacteria that was different from that isolated in the first
48 hours of treatment as the causal agent, and persisting for
at least two other cultures, not associated with a new infection
or clinical condition; (7) eradication with infection, when the
initial pathogen was eliminated, followed by the isolation of a
new pathogen or another serotype of the same microorganism,
with infection signs at the end of treatment; (8) presumed
persistence, defined as concurrent use of antibiotic therapy
due to persistent clinical symptoms and signs of infection, in
the absence of microbiological data; (9) undetermined, defined
as the absence of pathogen isolation in the initial sample,
absence of culture collection after Visit I, or patient not clinically
evaluable. Safety analysis was conducted in the sample of
patients that received at least one dose of the study drug
(safety population). All adverse events were noted throughout
the study. Serious adverse events were defined as any
occurrence that might have put the patient’s life at risk or
resulted in hospitalization, hospitalization extension, persistent
or significant impairment, teratogeny, or death. Safety analysis
parameters were evaluated throughout the study and were
based on the adverse event rate, early discontinuation,
laboratory changes, physical exam, and vital signs.
Statistical Analysis
Sample size was estimated based on cure rate at the end of
the study: 75%. Two-sided 95% CI for that rate with 20%
width could be obtained with a 73-patient sample. Assuming
loss to follow-up or non-evaluation of up to 20% of patients,
an 88-patient sample size would be required. Patient ratio for
each clinical and bacteriological response category was
obtained. A 95% CI, based on the normal approximation to the
binomial distribution, was calculated.
Results
Study Population
A total of 88 patients were selected, of those, 86 received
the proposed treatment. Forty five patients were male (51.2%)
and approximately 66% were white. Age range was 56.6 ± 19.8,
and average time from onset of pneumonia was 6.7 days (1 to
22 days). PSI mean score was 82.0 ± 26.2, ranging from 28.0 to
143.0. Most commonly found comorbidities were congestive
heart failure (15 patients), diabetes mellitus (14 patients),
chronic pulmonary obstructive disease (COPD) (13 patients)
and asthma (6 patients). Data on patients enrolled in the study
are summarized in Table 1.
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Table 1. Patients’ data at study starting point (N=86)
Of the 86 patients who were treated with the study drugs
62 (72.1%) reached study completion. A total of 24 patients
(27.9%) did not reach completion for the following reasons:
adverse events (13 patients – 15.1%); change in laboratory
Variable N (%)
Gender
Female  42 (48.8)
Male  44 (51.2)
Age (years)
Mean ±  SD 56.6 ± 19.8
Range 17 – 93
Race
White 56 (65.1)
Black 14 (16.3)
Mixed 16 (18.6)
Comorbidities
Congestive heart failure 15 (17.4)
Diabetes mellitus 14 (16.3)
Chronic pulmonary obstructive
 disease (COPD) 13 (15.1)
Asthma 6 (7.0)
Time from onset of symptoms (days)
Mean  ( range) 6.7 (1 – 22)
Pneumonia severity index (PSI)
Mean ±  SD 82.0 ± 26.2
Range 28 – 143
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testing (1 patient – 1.2%); no efficacy (1 patient – 1.2%); lost
to follow-up (1 patient – 1.2%); sudden death (1 patient –
1.2%); other reasons (7 patients – 8.1%). A total of 85 patients
were included in the Modified Intention to Treat (MITT)
population, made up of all patients that had been treated,
except those who were wrongly diagnosed or did not present
clinical symptoms at evaluation 1. 24 patients reported
microbiological data and were analyzed with reference to
bacteriological efficacy parameters.
Treatment Efficacy Evaluation
When the study started, pneumonia signs and symptoms
were presented as follows: cough – 95.3%; dyspnea – 84.7%;
pulmonary auscultation with rale – 89.4%; pleuritic pain –
64.7%; snoring at pulmonary auscultation – 28.2%; wheezing
– 27.1% and rigors – 27.1%. Pneumonia signs and symptoms
showed significant improvement at the end of treatment: cough
– 37.1%; rale – 16.1%; pleuritic pain – 9.7%; snoring – 6.5%
and dyspnea – 6.5%.
The number of patients who reported a positive clinical
response (cure or improvement) can be found in Table 2. The
number of patients who reported a positive bacteriological
response (eradication plus presumed eradication) is shown in
Table 3. Twenty four patients (27.9% of the study population)
made up the population that was modified for bacteriological
evaluation through hemoculture or sputum. The latter reported
a 6.67% and 11.11% rate of pneumococci that were resistant
to macrolides at the end of treatment and at the end of study
respectively. Only 1 patient used cefuroxime axetil rather than
azithromycin.
Fifteen patients were evaluated at the end of treatment. Of
those, 40% reported eradication, 53.3% reported presumed
eradication, and 6.7% reported presumed persistence.
At close of study out of the 18 patients that were evaluable
through microorganism isolation (sputum or hemoculture)
88.9% reported eradication or presumed eradication. (Table 3)
Table 4 shows clinical response to base pathogen in the
MITT population in patients whose pathogen was isolated.
Evaluation of pneumonia etiological agents that were identified
was as follows: at the end of the therapy, from patients infected
by Streptococcus pneumoniae 77.78% reported cure (7
patients) and 22.22% reported improvement (2 patients); of
those infected by Haemophilus influenza 100% reported
improvement (2 patients); of those infected by cure (9 patients)
reported cure and 14.29% reported failure. Of the 62 patients,
18 had etiological agents identified, as listed below.
Safety and Tolerability Evaluation
Of the 86 patients in the safety population, 64 patients
(74.4%) reported adverse events. Of those, the adverse events
reported by 33 patients (38.4%) were related to the study drug.
A total of 141 adverse events were observed. Of those, 55
(39%) were related to the study drug. Serious adverse events
were reported by 20 patients, but only two patients had their
serious adverse events – pneumonia condition worsening
and uncontrollable vomiting – related to azithromycin/
ceftriaxone. Both patients were discontinued from the study.
Of the 14 patients (16.3%) that were discontinued from the
study due to adverse events, 5 (5.8%) were discontinued due
to treatment-related adverse events. Most commonly found
adverse events were: no therapeutic response in 10 patients
(11.6%); pneumonia persistence in 7 patients (8.1%); increase
in transaminase levels in 6 patients (7.0%); pain at infusion
site in 5 patients (5.8%); epigastralgia in 5 patients (5.8%);
diarrhea in 5 patients (5.8%); vomiting in 5 patients (5.8%)
and hypertension in 5 patients (5.8%). A more detailed
description of drug-related adverse events and their severity
can be found in Table 5.
Discussion
Community Acquired Pneumonia is a high prevalence
condition, with a significant morbimortality rate and approximately
20% of cases resulting in hospital admittance [23].
The present study confirms that IV administration of
azithromycin associated to ceftriaxone and followed by oral
azithromycin has shown good clinical efficacy in treating CAP
inpatients. The possibility of changing to oral administration
after between 48 and 72 hours of parenteral treatment may
result in shorter hospital stay time.
Current studies support the macrolide - betalactamic
association. A number of studies of the treatment of CAP
recommend coverage for atypical agents as well as S.
pneumoniae, including Mycoplasma, Chlamydophila
pneumoniae (Chlamydia) and Legionella. Many Mycoplasma
or Chlamydophila pneumoniae (Chlamydia) infections are
self-limiting or are considered mixed infections that may
respond to betalactamics. Subgroup analysis in Legionella
infected patients shows that the therapeutic failure rate is
significantly lower in patients treated with antibiotics with
coverage for atypical agents.
Shefet et al. have conducted an analysis of 32 recent
studies involving 918 CAP patients who were treated with
amoxicillin, 2,940 treated with fluoroquinolone, and 2,018
treated with clarithromycin and azithromycin. Corresponding
rates demonstrated for clinical response were: 80%, 88%,
87.5%. Clinical response rates for treatment using
fluoroquinolones and macrolides were significantly higher
when compared to those using amoxicillin.
That makes the present study’s findings more material.
The data also show that for every 12 CAP patients treated
with amoxicillin 1 therapeutic failure was reported – and it
could have been prevented if a macrolide or a fluoroquinolone
[27] had been used.
A number of studies have tried to measure the impact of
treatment compliance for CAP outcome. However, none of
those studies were designed to evaluate specific antibiotic
therapy regimens.
The present study is not failure free. Major criticism may
be raised of the qualitative – rather than quantitative –
microbiological analysis, as well as of the fact that cultures
Azithromycin Plus Ceftriaxone Followed by Oral Azithromycin for the Treatment of CAP
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were not presented by collection site (hemoculture or sputum),
but by patient (eradication or persistence).
Some conclusions may be drawn, however, to be added to
the literature currently available.
Retrospective conventional studies suggest that treatment
using a macrolide combined, typically with a cephalosporin,
to form an initial therapeutic scheme for patients who need
hospitalization may be associated to lower mortality rate and
shorter hospital stay time when compared to treatment with
cephalosporin only [30,31].
Sanchez et al. conducted a prospective study in 2003
involving elderly patients with CAP. In the study, IV
administration of azithromycin and clarithromycin associated
to ceftriaxone was compared. Hospital stay time was 7.4 ±
5.0 days for the group treated with azithromycin, and 9.4 ±
7.0 days for the group treated with clarithromycin (p<0.01).
The mortality rate was also lower in the azithromycin group
when compared to the clarithromycin group (3.6% vs. 7.2%;
p<0.05). These data suggest the association azithromycin-
ceftriaxone to be more efficacious when compared to
clarithromycin [34].
The present study has shown that the combination of IV
azithromycin and ceftriaxone to treat CAP inpatients agreed
with previous publications, having shown 95.2% clinical
response at the end of treatment, and 82.9% at the end of the
study [31,35,36]. Approximately 75% of patients reported
some adverse event during the study, but only 38.4% were
related to azithromycin. From all serious adverse events only
2 were related to the study drug, and resulted in the
withdrawal of the two patients from the study. This data is in
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Table 2. Number of patients who presented a positive response to treatment with IV azithromycin followed by oral azithromycin
at day 10 of treatment (Visit III) and at the end of study (Visit IV).
Table 4. Clinical response to base pathogen – bacteriological MITT population.
Table 3. Bacteriological response distribution in patients reporting isolated microorganisms in sputum culture or hemoculture at
study start.
Clinical Response Visit III Visit IV
Patients evaluated 62 (100.0%) 70 (100.0%)
Cure 42 (67.7%) 58 (82.8%)
Improvement 17 (27.4%) 0
Failure 3 (4.8%) 12 (17.1%)
Positive clinical response (cure or improvement) 59 (95.2%) 58 (82.9%)
CI95% [88.9 – 100] CI95% [74.1 – 91.7]
Bacteriological response N (%)
Treatment end (Visit III) Patients evaluated 15 (100.0%)
Eradication 6 (40.0%)
Presumed Eradication 8 (53.3%)
Presumed Persistence 1 (6.7%)
Study end (Visit IV) Patients evaluated 18 (100.0%)
Eradication 9 (50.0%)
Presumed Eradication 7 (38.9%)
Undetermined 2 (11.1%)
Pathogen Visit Clinical response Azithromycin
Streptococcus pneumoniae End of therapy (Visit III) Cure improvement 7 (77.78%) 2 (22.22%)
Streptococcus pneumoniae End of study (Visit IV) Cure/failure/undetermined 9 (75%) 1 (8.33%)
2 (16.67%)
Haemophilus influenzae End of therapy (Visit III) Improvement 2 (100%)
Haemophilus influenzae End of study (Visit IV) Cure 2 (100%)
Staphylococcus aureus End of therapy (Visit III) Cure 1 (100%)
Staphylococcus aureus End of study (Visit IV) Cure 1 (100%)
Other pathogens End of therapy (Visit III) Cure/improvement/failure 4 (57.14%) 2 (28.57%)
1 (14.29%)
Other pathogens End of study (Visit IV) Cure/failure 6 (85.71%) 1 (14.29%)
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agreement with current literature, and has demonstrated the
concern with regard to pharmacosurveillance in the present
study.
In conclusion: azithromycin presents a good safety and
tolerability profile. Therefore, IV azithromycin associated to
ceftriaxone may be an appropriate therapeutic choice to treat
CAP patients who need hospitalization in Brazil. Currently,
the most widely accepted concept with regard to the starting
dose time frame for CAP patients who need hospitalization
is “the more septic the patient, the more likely it is that as
little as a 1 hour delay may impact mortality rate”. The
recommendation is that the first dose be administered at the
Emergency Service where the patient is seen for the first
time, rather than waiting for the patient to be admitted. That
would mean good conduct assistance and the best option
choice for the patient.
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